Vonoprazan improves the efficacy of bismuth quadruple therapy containing doxycycline and metronidazole as first-line <i>Helicobacter pylori</i> treatment in penicillin-allergic patients: a randomized controlled trial
The 14 day P-CAB/BDM therapy provided a satisfactory eradication rate of >90% (ITT analysis) and had a good safety profile as first-line H. pylori therapy, providing an alternative option for penicillin-allergic patients.
Authors
- Dan Ma (ORCID: https://orcid.org/0000-0001-8628-8954)
- Kefang Sun
- Ye Chen (ORCID: https://orcid.org/0000-0002-7964-7899)
- Lan Li (ORCID: https://orcid.org/0000-0001-8401-4001)
- Jinghua Wang (ORCID: https://orcid.org/0000-0003-2619-0570)
- Qing Gu (ORCID: https://orcid.org/0000-0001-5394-6615)
- Renke Zhu
- Jianguo Gao (ORCID: https://orcid.org/0009-0006-4627-9803)
- Jiewei Wang (ORCID: https://orcid.org/0009-0002-8184-7926)
- Tianlian Yan
Institutions
- Northern Arizona University (US)
- Rochester General Hospital (US)
- First Affiliated Hospital Zhejiang University (CN)
- Zhejiang University (CN)
Publication Details
- Journal
- Journal of Antimicrobial Chemotherapy
- Published
- 2025-03-06
- DOI
- https://doi.org/10.1093/jac/dkae467
- Citations
- 3
- Primary Topic
- Helicobacter pylori-related gastroenterology studies
- Type
- article
- Field-Weighted Citation Impact
- 6.02
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Zhejiang Province